An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
Phase of Trial: Phase II/III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Aug 2014.
- 27 Sep 2012 Planned End Date changed from 1 Jul 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.